I am not a statistician but difficult to see how the phase 1 top line results won't be good if the recent feedback from the CEO is anything to go by re the 12 patients on phase 1 treatment - i.e. all still on the treatment, not needing respiratory support meaning they continue to remain well enough to continue treatment and most having been on the treatment for as long as or longer than the current average survival on the approved standard of care.
Ann: PAA completes Phase 1 and files for Orphan Drug Designation, page-197
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.42M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.3¢ | 19.0¢ | $25.41K | 133.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5372 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 262575 | 3 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |